These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9865253)

  • 1. Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients.
    Preuner JG; Lehle K; Keyser A; Merk J; Rupprecht L; Goebels R
    Transplant Proc; 1998 Dec; 30(8):3943-4. PubMed ID: 9865253
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients.
    Jennings DL; Martinez B; Montalvo S; Lanfear DE
    Heart Fail Rev; 2015 Sep; 20(5):573-8. PubMed ID: 25925244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction.
    Cantarovich M; Quantz M; Elstein E; Ergina P; Magnan C; de Varennes B
    Transplant Proc; 2000 Mar; 32(2):446-8. PubMed ID: 10715475
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 5. First-pass metabolism of cyclosporine A in human intestine: inhibition by diltiazem.
    Preuner JG; Lehle K; Eichinger H; Rupprecht L
    Transplant Proc; 1998 Sep; 30(6):2545-6. PubMed ID: 9745480
    [No Abstract]   [Full Text] [Related]  

  • 6. Intestinal metabolism of cyclosporine A in human heart transplant recipients.
    Lehle K; Kirchner G; Sewing KF; Rupprecht L; Merk J; Preuner JG
    Transplant Proc; 1998 Dec; 30(8):4044. PubMed ID: 9865289
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucose metabolism in heart transplant recipients treated with FK506 or cyclosporine.
    Sahar G; Berman M; Ben-Gal T; Sahar E; Kogan A; Michowitch R; Saute M; Kramer M; Sagie A; Shapira Y; Aravot D; Vidne BA
    Transplant Proc; 2003 Mar; 35(2):678. PubMed ID: 12644092
    [No Abstract]   [Full Text] [Related]  

  • 8. C(2) monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses.
    Baraldo M; Francesconi A; Barbone F; Tursi V; Livi U; Furlanut M
    Transplant Proc; 2002 Dec; 34(8):3246-8. PubMed ID: 12493435
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of Sandimmune cyclosporine on renal blood flow and function in heart transplant recipients.
    Chung G; Walker S; Vadher B; Murphy F; Leaver N; Banner N
    Transplant Proc; 1998 Jun; 30(4):1147-8. PubMed ID: 9636464
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine neoral monitoring and its correlation with the "area under the curve".
    Sabbatiello R; Sgrosso JL; Schiavelli R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3378. PubMed ID: 8962317
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
    Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
    Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcineurin inhibitors in heart transplantation.
    Crespo-Leiro MG
    Transplant Proc; 2005 Nov; 37(9):4018-20. PubMed ID: 16386614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients.
    van Besouw NM; Vaessen LM; Balk AH; Mochtar B; Claas FH; Weimar W
    Transplant Proc; 1996 Dec; 28(6):3135-6. PubMed ID: 8962214
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical impact of Neoral in thoracic organ transplantation.
    Aziz T; el-Gamel A; Keevil B; Krysiak P; Campbell C; Rahman A; Deiraniya A; Yonan N
    Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326
    [No Abstract]   [Full Text] [Related]  

  • 17. C(2) blood levels in heart-transplanted patients immunosuppressed on a trough level-based regimen.
    Fiocchi R; Iamele L; Torre L; Papageorgiou C; Gamba A; Ferrazzi P
    Transplant Proc; 2001; 33(7-8):3115-6. PubMed ID: 11750339
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
    Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
    Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of monitoring trough and peak cyclosporine levels in heart transplantation.
    Ballesteros S; Lage E; Villa M; Ordóñez A; Borrego JM; Gutierrez E; Hernández A; Hinojosa R; Cisneros JM
    Transplant Proc; 2003 Mar; 35(2):727-8. PubMed ID: 12644113
    [No Abstract]   [Full Text] [Related]  

  • 20. Dronedarone: a review of characteristics and clinical data.
    Baroletti S; Catella J; Ehle M; Cheng JW
    Crit Pathw Cardiol; 2010 Jun; 9(2):94-101. PubMed ID: 20520217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.